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1. INTRODUCTION AND AIMS 
 
β-Amino acids are in the limelight of current interest due to their valuable 
pharmacological properties. They serve as essential structural units of a number of 
biologically active compounds, found in natural products. Naturally occurring cyclopentane-
based β-amino acids, such as cispentacin1-10 and icofungipen1-10, are strong antifungal agents, 
while the cyclohexane amino acid Tamiflu11 and the O-heterocyclic amino acid Zanamivir12 
exert notable antiviral activities. These compounds serve as building blocks of β-lactams, 
antibiotics and peptides. Open-chain β-amino acids, and particularly β2,3-amino acids, a 
subclass of β-amino acids, are also structural elements of natural products with activity 
against leukemia, e.g. Dolastatin 11, 12, 16 and D13, Majusculamide C14 and Onchidin15, 
natural antitumoural agents such as Guineamide C and D16, Ulongapeptin17 and Malevamide 
C17-39. 
The Institute of Pharmaceutical Chemistry at the University of Szeged has extensive 
experience in the field of the synthesis and transformation of β-amino acids. The research is 
focused on the development of stereoselective approaches towards highly functionalized 
alicyclic and open-chain β-amino acid derivatives. The regio- and stereoselective syntheses of 
mono- and dihydroxylated, mono- and difluorinated, protected amino, epoxy, azido, 
isoxazoline alicyclic β-amino acid derivatives, starting from the appropriate alicyclic 
unsaturated β-lactams have been successfully accomplished by C-C ring double bond 
functionalization40-54 (Figure 1).     
 
Figure 1. Selected examples of the functionalization of cyclic β-amino acid derivatives 
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Although numerous methods have been reported for the synthesis of β-amino acid 
derivatives, the development of new regio-, stereocontrolled, efficient approaches towards 
highly functionalized enantiomerically pure species still remains an important goal.  
 
 
 
Figure 2. Reactions investigated in the present PhD work  
 
The present PhD work was focused on the development of stereocontrolled synthetic 
strategies to novel enantiomerically pure disubstituted alicyclic β-amino esters derived from 
norbornene-based diendo- and diexo-β-amino carboxylates and acyclic β2,3-substituted amino 
acid derivatives from cis or trans cyclopentene and cyclohexene β-amino acids. The method 
is based on functionalization of the ring C-C double bond of the β-lactam through 
dihydroxylation, and oxidative C-C bond cleavage of the vicinal diol, followed by Wittig 
transformation with different phosphoranylides and reduction of the olefinic bond. All 
products were obtained in both racemic and optically pure forms (Figure 2). 
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2. LITERATURE BACKGROUND 
Synthetic routes towards β2, 3-amino acids 
Since the Institute of Pharmaceutical Chemistry has gained considerable experience in 
the synthetic elaboration of functionalized cyclic β-amino acid derivatives, and a significant 
number of papers have been published on this field55, the current literature survey is focused 
on the synthesis of open-chain β-amino acids, and particularly β2,3-amino acid derivatives. 
The most relevant synthetic procedures will be highlighted below.  
 
2.1. Homologation of α-amino acids via Wolff rearrangement of  
        α-alkylated-α-diazoketones 
The Wolff rearrangement is one of the most practical reactions for elongation of the 
carbon chain of carboxylic acids by one carbon atom. Yang et al. reported a synthesis of β2,3-
dialkylated β-amino acids through the photo-induced Wolff rearrangement56. The α-alkyl-α-
diazoketone 2 required as precursor for the reaction was synthetized from the corresponding 
α-amino acid 1 through diazomethane coupling, followed by an anionic alkylation reaction. 
The subsequent Wolff rearrangement was triggered by UV light at -78 °C to give a ketene 
intermediate, which was further trapped by alcohol to furnish the desired β2,3-amino acid 
derivatives (Scheme 1). 
 
Scheme 1. Homologation of α-amino acids via the Wolff rearrangement  
 
The stereochemistry of the major diastereomer was determined to be anti.  The steric 
size of the substituents plays a crucial role in the stereoselectivity of this reaction.  
 
2.2. Curtius rearrangement of 2,3-disubstituted 1,4-dicarboxylic acids 
The Curtius rearrangement provides access to di- or trisubstituted β-amino acid 
derivatives through a carboxyl → amine conversion.  
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Scheme 2. Synthesis of α-hydroxy β2,3-amino acids via the Curtius rearrangement 
Roers and co-workers reported the synthesis of syn and anti α-hydroxy β2,3-amino 
acids (syn-8 and anti-8) via a modified Curtius rearrangement, utilizing DPPA (diphenyl 
phosphoryl azide) as an azide source (Scheme 2). The synthetic sequence includes a 
stereoselective aldol reaction catalysed by chiral Sn(II) and Cu(II) complexes, which allows 
the preparation of syn-6 and anti-6 precursors in an optically pure form with e.e. up to 91%. 
The modified Curtius rearrangement leads to oxazolidinones syn-7 and anti-7 through an 
isocyanate intermediate, which undergoes further intramolecular cyclization. After Boc 
protection, the cyclic oxazolidinones were submitted to basic hydrolysis in order to obtain the 
target β2,3-amino acids syn-8 and anti-8 in good yields57. 
A further example of the Curtius rearrangement-based approach is the synthesis of 
iturinic acid and 2-methyl-3-aminopropanoic acid as reported by Sibi and Deshpande. They 
described a stereo- and chemoselective carboxyl group conversion into an amino group in 
alkyl-substituted succinates, while the other carboxyl group was protected by a chiral 
auxiliary58. Similar methodology was applied by the Evans group in order to obtain both β-
alkyl and β-aryl amino acid species with high enantiomeric excess59. Balamurugan et al. 
described the preparation of trans-β2,3-amino acids via an anti-selective aldol reaction, 
azidation and controlled hydrolysis of the chiral auxiliary60.  
 
2.3. Ring opening of disubstituted β-lactams 
The single-step conversion of 2,3-disubstituted β-lactams provided a direct access 
route to β2,3-amino acids, although the synthesis of the precursor β-lactams in stereo- and 
chemoselective fashion still remains a synthetic challenge. It should be noted that the use of 
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N-acyl β-lactams is preferable, since the acyl group enhances the β-lactam carbonyl reactivity 
towards nucleophilic attack and serves as a protecting group of the newly formed amino 
function29. 
Musso et al. described a synthesis of formamido acid derivative 10 via hydrolysis of β-
lactam 9 in basic aqueous media, followed by an N-formylation reaction61 (Scheme 3).  
 
 Scheme 3. Ring opening of a β-lactam via basic hydrolysis 
Ojima and co-workers reported a hydrolysis of β-lactam under acidic conditions to 
afford enantiomerically pure α-alkylisoserine hydrochlorides62. For substrates showing high 
instability in strong basic media, mild alcoholysis in the presence of NaN3 or KCN can be an 
alternative, demonstrated by Palomo et al63. 
 
2.4. Oxidation of 2,3-disubstituted 1,3-amino alcohols 
Sabala et al. recently reported the oxidation of dialkylated amino alcohol 11 into an N-
protected amino acid 12 by means of NaIO4, with a catalytic amount of RuCl3 and 
enantiomerically pure starting materials (Scheme 4)64. The same strategy was earlier applied 
by the Davis group for the synthetic generation of dialkylated N-Ts-protected amino acids in 
asymmetric fashion with good yields65. 
 
Scheme 4. Oxidation of 1,3-amino alcohols by NaIO4 and RuCl3 
 
The Swern–Pinnick oxidation of 1,3-amino alcohol 13, demonstrated by Meiries et al., 
resulted in α-methyl-β-vinyl β-amino acid derivative 14. The first step involved Swern 
oxidation of the primary alcohol to the aldehyde, using dimethyl sulfoxide activated by oxalyl 
chloride. Further Pinnick oxidation of the aldehyde group into the carboxylic acid was 
performed by treatment with NaClO2  and NaH2PO4 (Scheme 5)66.  
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Scheme 5. Swern–Pinnick oxidation of amino alcohol 13 
 
The disadvantage of the procedure was the significant level of epimerization that 
occurred in the course of the Swern oxidation, resulting in an inseparable 5:3 mixture of 
syn/anti diastereomers. 
 
2.5. Alkylation of β3-amino acid derivatives 
 
A highly diastereoselective synthesis of β2,3-dialkylated amino acid derivatives can be 
achieved through the direct alkylation of β3-amino acids. Capone et al., for instance, described 
a versatile synthesis of anti-α,β-dialkyl β-amino acid 16 by exploiting the α-acidity of the β3-
amino acid derivative 1567. Deprotonation of the active methylene first took place, leading to 
enolate formation, which is followed by treatment with methyl iodide (Scheme 6).  
 
Scheme 6. Alkylation of β3-amino acid derivatives 
 
The high anti diastereoselectivity obtained can be explained by the presence of two N-
protective groups, which help to avoid side-reactions in the basic reaction medium. The 
formation of a Z-enolate, providing the more stable conformation, can account for the 
excellent diastereoselectivity through the alkylation from the less hindered face. 
This methodology was successfully applied in a number of additional papers, including 
the preparation of the disubstituted 3-aminobutanoic acids as starting materials for enzymatic 
resolution by Cardillo et al.68, the synthesis of dialkylated amino esters of methionine, 
allylglycine and serine by Gardiner and co-workers69, and dialkylated 3-aminobutanoic acid 
synthesis by Heinrich and Seebach70. 
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2.6. Rearrangement of imides with hypervalent iodine reagents 
 
Aliphatic amides can be transformed into aliphatic amino acid derivatives via the 
Hoffmann rearrangement. Two recent synthetic variations of this reaction are known and 
presented herein. The first method describes the synthesis of dialkylated β-amino acid 
derivatives by means of hypervalent iodine(III) generated in situ from an iodoarene and an 
oxidant (Scheme 7)71. The rearrangement involves the formation of an imide-hypervalent 
iodine(III) complex, followed by ring opening of the imide. The proposed mechanism 
includes the oxidation of iodobenzene by m-CPBA in the presence of TsOH.H2O, followed by 
formation of the imide-λ3-iodane intermediate through the reaction with imide under basic 
conditions. The ring opening leads to formation of an isocyanate, and subsequent alcohol 
addition yields the β2,3-amino acid species 18. 
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Scheme 7. Hoffmann rearrangement of imides with hypervalent iodine reagents 
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The second method introduces a Hoffmann rearrangement of imides via the oxidation of 
alkali metal halides72. KBr was used as a bromine source, which was oxidized by t-BuOCl in 
order to generate bromine chloride in situ. N-Bromo imide formation then takes place, 
followed by ring opening, and the Hoffmann rearrangement affords the isocyanate. The 
corresponding carbamate 18 is next formed via bromide elimination and addition of alcohol. 
The eliminated bromide is oxidized to bromine chloride by t-BuOCl, and participates in a new 
catalytic cycle. This method allows the synthesis of desired products without halogen-
containing organic waste.  
Saavedra et al. reported another methodology for the preparation of dialkylated β-amino 
acid derivatives from α-amino acids via a one-pot scission-oxidation-Mannich reaction73. 
 
2.7. Reaction of carboxylic acid esters with imidoyl chlorides 
 
One specific application towards disubstituted β-amino acid derivatives is based on the 
reactions between carboxylic acid esters with imidoyl chlorides described by Fustero’s 
group74. The synthetic protocol used for the preparation of the imidoyl chlorides was 
previously described by Uneyama et al.75. The first step in the Fustero synthesis, depicted in 
Scheme 8, includes enolate formation by the treatment of pentenoic esters with LDA, 
followed by a direct Mannich-like reaction that gives β-amino ester 21 after work-up. The 
final product 21 was isolated as a mixture of imino-enamino tautomers 21 and 22. 
 
Scheme 8. Reactions of carboxylic acid esters with imidoyl chlorides 
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Subsequent reduction with sodium cyanoborohydride as reducing agent proved to be 
best in terms of the isolated yield, but the reaction did not display any stereoselectivity, since 
both diastereomers were obtained, in 1:1 ratio.  
 
2.8. Michael addition of chiral amines to α, β-unsaturated esters 
 
The Michael addition of chiral lithium amides to α,β-unsaturated esters serves as a 
powerful synthetic tool for the preparation of β-amino acid derivatives. Davies and co-
workers were the first to demonstrate the stereoselective 1,4-conjugate addition of optically 
pure lithium amide (R)-25 to disubstituted ester 24 with a d.e. >95%, followed by protection 
group cleavage with H2 and Pd(OH)2/C, and ester hydrolysis furnished enantiomerically pure 
dimethyl-β-amino acid 27 (Scheme 9)76.  
 
Scheme 9. Michael addition of lithium amide 25 to α,β-unsaturated ester 24 
 
The high diastereoselectivity can be envisioned in terms of a proposed model (Figure 3), 
wherein the lowest energy transition state belongs to the α,β-unsaturated ester with an s-cis 
conformation. The lithium is chelated to both the carbonyl oxygen and the nitrogen lone pair, 
and the two phenyl groups are situated almost parallel to each other. In this case the si-face 
addition is the favourable process, resulting in pronounced stereoselectivity. 
 
Figure 3. Proposed transition model of the lithium amide-α,β-unsaturated ester complex 
 
The hydrogenolysis applied in the final step often cannot be used in the cases of 
substances containing certain functionalities, such as a π-bond, in consequence of likely 
undesired reductions. In order to avoid these side-reactions, the utilization of milder 
  10 
protecting group chemistry is required. One such example of the synthesis of β2,3-amino acid 
derivatives, introducing N-allyl protecting group chemistry, is that reported by Chippindale et 
al77. First, conjugate addition of chiral allylated lithium amide (R)-29 to (E,E)-tert-butylhexa-
2,4-dieneoate 28 gave access to 30 in a yield of 78% and >95% d.e. (Scheme 10).  
 
Scheme 10. Michael addition of chiral amide 29 to ester 28 
 
The next step involved a deprotonation of N-allyl β-amino ester 30 by LDA, and 
subsequent allylation with allyl bromide led to an inseparable mixture of anti and syn 
diastereomers in 75% d.e. Subsequent deallylation by Wilkinson’s catalyst produced a 
mixture of secondary amines, which could be separated by means of column chromatography, 
furnishing the major anti diastereomer 32 in >95% d.e.  
This approach was further successfully applied by Bentley et al. in order to obtain 
β
2,2,3
-trisubstituted amino acids via conjugate addition of a “hydroxylamine equivalent” 
lithium amide to β-alkyl and β-aryl α,β-unsubstituted esters78,79. Ozeki et al. reported a 
synthesis of β-amino-β’-hydroxy esters through the Michael addition of N-benzyl-2(R)-
methoxy-(+)-10-bornylamide to α,β-unsaturated esters80. 
 
2.9. Dipolar cycloaddition of nitrile oxides to olefins 
 
Chiral isoxazolinones serve as key intermediates for the synthesis of various highly 
substituted β-amino acid derivatives. Their stereoselective synthesis can be achieved through 
1,3-dipolar cycloaddition of a nitrile oxide and a chiral allylic alcohol, originally described by 
Kanemasa et al.81. A general strategy for the synthesis of β-amino acids from isoxazolines is 
depicted in Scheme 11. Cycloaddition of nitrile oxide 33 and allyl alcohol 34 followed by 
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reduction gave isoxazolidine 36. Subsequent reductive cleavage of the N-O bond, followed by 
oxidative C-C bond cleavage of the diol 37, furnished the final product amino acid 38.  
 
Scheme 11. General scheme of the isoxazoline strategy towards the synthesis of β-amino 
acids 
 
On the basis of the above-mentioned procedure, Minter and co-workers reported a 
similar route to dialkylated β2,3-amino acids (Scheme 12)82. First, isoxazoline 39 was gained 
via 1,3-dipolar cycloaddition of a nitrile oxide, generated in situ from the corresponding 
oxime, to a magnesium allyl alcoholate. Compound 39 was then reduced with LiAlH4 in THF, 
and subsequent one-pot N-protection afforded amino diol 40 as a mixture of diastereomers. 
Oxidative C-C bond cleavage with NaIO4 and RuCl3 gave diethyl-N-Boc-protected β-amino 
acid 41 in 67% d.e. The method was supported by theoretical considerations and further 
extended to the synthetic generation of various substrates by the same group83, 84.    
 
 
Scheme 12. Reduction of isoxazoline 39 and further oxidation to β-amino acid 41 
 
One more intriguing example of asymmetric disubstituted β-amino acid synthesis via 
dipolar cycloaddition was presented by Sibi and co-workers85. The first step in the synthesis 
involved a Lewis acid-catalysed aza-Michael addition of N-benzylhydroxylamine to α,β-
disubstituted imide 42, and intramolecular SN acyl lactonization then resulted in the formation 
of isoxazolidinone 44 (Scheme 13). The active Lewis acid catalyst formed in situ was derived 
from the chiral bis-dihydro-oxazole framework 43 as ligand and a magnesium salt. The high 
stereocontrol of the aza-Michael addition is proven by the chiral ligand, which provides 
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sufficient steric hindrance, and the subsequent addition of nitrogen occurs on the Re face of 
the β-carbon.  
 
Scheme 13. Enantioselective synthesis of β-amino acid 45 through cycloaddition  
 
The reductive ring cleavage of isoxazolidinone 44 through Pd/C-catalysed 
hydrogenolysis furnished dimethyl-β-amino acid 45 in optically pure form. 
 
2.10. Asymmetric hydrogenation of β-enamino esters 
 
Catalytic asymmetric hydrogenation or reduction of β-enamino esters is a practical 
method for the preparation of optically pure β-amino carboxylates in the presence of chiral 
ruthenium(II) or rhodium(I) complexes86. A large number of catalytic systems have been 
developed in order to improve the yields and stereoselectivities87, including rhodium-based 
catalysts with mono- and bidentate ligands88-93, and chiral phosphine-based ruthenium 
catalysts94,95.  
To the best of our knowledge, the first approach towards dialkylated β2,3-amino acid 
derivatives was developed by Cimarelli et al.96 in 1996. In that paper, the diastereoselective 
reduction of prochiral β-enamino ester 46 was performed in the presence of NaHB(OAc)3 in 
acetic acid, affording the syn β-amino ester 47 in 72% d.e. (Scheme 14). 
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Scheme 14. Reduction of β-enamino ester 46 to β-amino ester 47 with NaHB(OAc)3/AcOH 
 
A ruthenium-catalysed hydrogenation methodology towards dialkylated β-amino esters 
was reported by Tang and co-workers97. They described the hydrogenation of enamide (Z)-48 
by means of a ruthenium(II) catalyst generated in situ by ligand exchange of Ru(COD)-
(methallyl)2 and a (S)-C3-TunaPhos chiral ligand. The reaction, performed under 50 atm 
hydrogen pressure in EtOH, resulted in the (2S,3R)-threo isomer in 72% e.e. (Scheme 15). 
The application of other chiral ligands, such as BINAP, MeO-BIPHEP, C2-, C4-, or C5-
TunaPhos, provided similar results in terms of enantioselectivity.  
 
Scheme 15. Hydrogenation of β2,3-enamide 48 with Ru-(S)-TunaPhos as catalyst 
 
The above work was extended by Elaridi and co-workers in order to obtain the erythro 
derivative98. Asymmetric hydrogenation of enamide (E)-48 in the presence of the chiral 
rhodium catalyst (R,R)-Me-BPE-Rh(I) in methanol at 60 psi hydrogen pressure gave the 
(2R,3R)-erythro derivative 50 in 48% e.e. (Scheme 16).  
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Scheme 16. Hydrogenation of β2,3-enamide 48 catalysed by Rh-Me-BPE 
 
The reaction was then further optimized, and the highest e.e. of 65% was obtained with 
benzene as solvent at 90 psi hydrogen pressure.  
 
2.11. Addition of carboxylic acid derivatives or aldehydes to aldimines 
 
The asymmetric Mannich reaction is a powerful tool for the preparation of optically 
active β-amino acid derivatives. Lewis acids are often employed to activate the aldehyde or 
the imine and to control the stereoselectivity. Morimoto and co-workers reported the 
improved rare metal-based enantio- and diastereoselective Mannich reaction depicted in 
Scheme 1799. 
 
Scheme 17. Lanthanum aryloxide/pybox ligand–catalysed Mannich reaction 
 
In this work, 1,1,1-trichlorobutan-2-one 52 was used as a Mannich donor in the reaction. 
A new lanthanum aryloxide-i-Pr-pybox + lithium aryloxide catalyst was introduced, giving 
syn-adduct 53 in 96% e.e. and syn:anti = 21:1 d.r. 
While several successful examples of the chiral Lewis acid activation of aldehydes have 
been reported, few examples are known for imine activation by Lewis acids, probably due to 
the different coordination manner. Lewis acid coordinates the aldehyde from the syn face of 
the hydrogen atom of the aldehyde, but in the case of the imine the Lewis acid can coordinate 
either from the syn or from the anti direction of the imine hydrogen atom. Kobayashi et al. 
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reported an example of effective imine activation in a Mannich reaction by means of a chiral 
zirconium catalyst (Scheme 18)100. 
 
Scheme 18. Chiral zirconium–catalysed Mannich reaction  
 
The Mannich reaction between imine 54 and silyl enolate 55, catalysed by zirconium 
complex 56, derived from Zr(OtBu)4, (R)-3,3’-BrBINOL, afforded the Mannich adduct 57 in 
99% yield and 69% e.e. It should be mentioned that the use of water as an additive 
dramatically increased the enantiomeric excess up to 95%. The high enantioselectivity can be 
explained by the bidentate coordination of imines to the chiral zirconium catalyst, then silyl 
enolate interaction with the zirconium, and further attack on the stereo-activated imine 
furnishes product 57, along with regeneration of the catalyst. 
A further interesting example of highly diastereo- and enantioselective Mannich 
reactions, depicted in Scheme 19, was described by Vicario and co-workers101. Propionamide 
derivative 58 was deprotonated with LDA, and further reacted with imine 59, yielding anti 
diastereomer β-aminoamide 60 with a d.r. of >99:1. It should be mentioned that the presence 
of LiCl plays a crucial role in the stability and reactivity control of the enolate; in its absence 
no reaction occurred. Amide 60 was transformed into optically pure disubstituted β-amino 
ester 61 through a hydrolysis-esterification sequence. Importantly, no racemization was 
observed during the transformations. 
 
Scheme 19. Mannich reaction between the (S,S)-(+)-pseudoephedrine propionamide-derived 
compound  58 and imine 59 
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Besides Lewis acid-catalysed Mannich reactions, a number of organocatalysts with 
such advantages as stability towards water and oxygen have been developed. Chiral Bronsted 
acids act as stronger electrophilic activators as compared with hydrogen-bond activation-
based organocatalysts. A versatile Bronsted acid-catalysed Mannich reaction was recently 
reported by Yamanaka et al.102 (Scheme 20). Catalyst 63 was prepared from (R)-BINOL. 
Aldimine 54 was reacted with ketene silyl acetal 62 in the presence of a catalytic amount of 
Bronsted acid 63, giving the corresponding Mannich adduct 64 in 96% e.e.  
 
Scheme 20. Chiral Bronsted acid-catalysed Mannich reaction 
 
Several examples of highly efficient proline-catalysed Mannich reactions have also been 
reported, including the synthesis of α-hydroxy-β-amino acids by Dziedzic and co-workers103 
and 2,3-dialkylated β-amino acids synthesis by Yang et al.104. The latter approach is 
illustrated by the Mannich reaction between benzaldehyde-derived N-Boc-imine 66 and 
hexanal 65 in the presence of (S)-proline, affording the dialkylated product 67 in >99:1 d.r. 
and >99:1 e.r. Compound 67 was then readily converted into the corresponding β-amino acid 
68 by Pinnick oxidation and acid-mediated deprotection procedures (Scheme 21). 
 
 
Scheme 21. Proline-catalysed Mannich reaction 
 
The reaction catalysed by proline proved to be highly stereoselective and practical, as it 
does not require chromatographic purification. The current limitation of the process is that 
aliphatic imines cannot be used as reactants. 
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2.12. Addition of ester enolates to chiral sulfinylimines 
 
One promising method for the preparation of disubstituted β-amino carboxylates is the 
addition of ester enolates to sulfinylimines, which proceeds with high yields and 
diastereoselectivities; moreover, the sulfinyl group can be removed with ease by treatment 
with HCl in protic solvents. Several studies in this field have been published by Davis et 
al.105-107. In order to obtain α,β-dialkylated β-amino Weinreb amide 71, addition of prochiral 
Weinreb amide enolate 70 to chiral sulfinylimine 69 was performed, resulting in a 4:1 mixture 
of syn-anti diastereomers 71. The diastereomeric mixture could then be separated, affording 
the major syn diastereomer in 76% yield. Selective removal of the N-sulfinyl group was next 
performed by HCl in MeOH, yielding amide 72, which was further N-tosylated and 
hydrolysed to give the desired β-amino acid 74 (Scheme 22). 
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Scheme 22. Addition of Weinreb amide 70 to sulfinimine 69 
 
The addition of titanium enolates of carboxylic esters to sulfinylimines, described in the 
work of Tang et al.108, afforded N-sulfinyl β-amino esters with high diastereoselectivities up 
to 99:1. The N-sulfinyl β-amino ester 77, formed as a single diastereomer in 90:10 d.r., 
underwent an N-deprotection procedure to give access to amino acid ester 78 (Scheme 23). 
Scheme 23. Addition of ester 76 to sulfinylimine 75 
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2.13. Ring opening of 4,5-dialkyl-1,3-oxazinan-6-ones 
 
The ring opening of 4,5-dialkyl-1,3-oxazinan-6-ones provides access to a diverse range 
of β2,3-disubstituted amino acid derivatives109,110. The synthesis of 1,3-oxazinan-6-one 82 is 
depicted in Scheme 24. First, β-amino acid 81 was prepared through Arndt-Eistert 
homologation of α-amino acid 79. Acid-catalysed cyclization of N-protected β-amino acid 81 
then resulted in the desired intermediate 82. Further alkylation of 82 in the presence of 
KHMDS and MeI furnished 5-alkyl-1,3-oxazinan-6-one 83 in a 19:1 trans:cis d.r. The 
diastereomers formed were separated by crystallization. The reductive cleavage of 83 
proceeded smoothly, affording the N-protected β2,3-disubstituted amino acid 84. 
CbzHN CO2H
Me
1. EtOCOCl, NMM
2. CH2N2, (CH2O)n,
cat. CSA, C6H6, reflux
CbzHN
Me
CHN2
O
AgO2CCF3, H2O,
sonication CbzHN
Me
CO2H
(CH2O)n, cat. CSA,
C6H6, reflux
N
O
OCbz
Me
79 80 81
82
1. KHMDS, THF,
HMPA
2. MeIN
O
OCbz
Me
83, 19:1 d.r. (trans:cis)
Me
TFA, Et3SiH,
CH2Cl2CbzHN
Me
CO2H
Me
84
 
Scheme 24. Synthesis of β2,3-disubstituted amino acid derivative 84  
via 1,3-oxazinan-6-one 82 
 
Different approaches towards the ring opening of 1,3-oxazinan-6-ones can give access 
to numerous disubstituted β-amino acid derivatives (Figure 4). The manipulations presented 
highlight the versatility of oxazinanones. 
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Figure 4. Oxazinanone ring openings 
 
A wide range of synthetic strategies towards β2,3-disubstituted amino acid derivatives 
were described above; most of them are efficient and versatile. However, a number of 
limitations should still be emphasized, including in some cases an insufficient level of 
reaction stereocontrol, the availability of properly substituted reactants, the possibility of 
large-scale synthesis, the difficulty of the experimental procedures, and the cost of the 
materials used.  
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3. RESULTS AND DISCUSSION 
3.1. Synthesis of racemic and enantiomerically pure starting materials 
 
The synthetic preparation of racemic dihydroxylated diexo-β-amino ester (±)-88 as required 
starting material is depicted in Scheme 25. First, bicyclic β-lactam (±)-86 was synthetized by N-
chlorosulfonyl isocyanate (CSI) addition to norbornadiene, followed by chlorosulfonamide 
hydrolysis with Na2SO3111. The lactam ring was then opened at 0 °C with ethanolic HCl solution, 
and subsequent N-benzoyl protection resulted in diexo-β-amino ester (±)-87112. Further cis-
selective dihydroxylation of (±)-87 in the presence of a catalytic amount of OsO4 and N-
methylmorpholine N-oxide (NMO) as co-oxidant yielded dihydroxylated diexo-β-amino ester (±)-
88 (for the analogous transformation of Boc-protected β-amino esters, see reference 40).  
 
 
Scheme 25. Synthesis of dihydroxylated diexo-norbonane β-amino ester (±)-88 
 
Bicyclic diendo-β-amino acid (±)-90 was obtained from bicyclic diendo-anhydride (±)-89 
via a ring opening reaction with NH3, followed by Hoffmann degradation113. The subsequent 
esterification procedure with EtOH and SOCl2 and N-benzoyl protection gave diendo-β-amino 
ester (±)-91112. Stereoselective dihydroxylation of (±)-91 by means of NMO and a catalytic 
amount of OsO4 furnished the dihydroxylated diendo-β-amino ester (±)-92 (Scheme 26)40. 
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Scheme 26. Preparation of dihydroxylated diendo-norbornane β-amino ester (±)-92 
 
Cyclopentene-fused β-lactam (±)-94 was prepared from cyclopentadiene (±)-93 through CSI 
addition, followed by NaSO3-mediated hydrolysis114. The β-lactam (±)-94 was further 
transformed into a β-amino carboxylate (±)-95 through ring opening with ethanolic HCl solution 
and benzoylation115. Base-induced inversion of cis derivative (±)-95 with NaOEt resulted in the 
  21 
trans form (±)-97. Further dihydroxylation of both cis- and trans-β-amino esters yielded the 
corresponding vicinal diols (±)-96 and (±)-98 (Scheme 27)115. 
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Scheme 27. Synthesis of dihydroxylated cis and trans cyclopentane-based β-amino esters 
 
The synthesis of 1,4-unsaturated cyclohexadiene-derived β-lactam (±)-100 was achieved 
from the corresponding 1,4-cyclohexadiene (±)-99 by CSI addition116. Ring opening followed by 
N-benzoylation afforded β-amino ester (±)-101117. When (±)-101 was subjected to NaOEt-
mediated inversion, it gave trans derivative (±)-103. Stereoselective double bond dihydroxylation 
gave access to the corresponding diols (±)-102 and (±)-104 (Scheme 28). 
 
 
Scheme 28. Synthesis of dihydroxylated cis and trans cyclohexane-based β-amino esters 
 
The 1,3-unsaturated cyclohexadiene-derived β-lactam (±)-106 was prepared from the 1,3-
cyclohexadiene (±)-105116. Ring opening followed by group protection afforded β-amino ester 
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(±)-107117. Stereoselective double bond dihydroxylation gave access to the corresponding diol 
(±)-108 (Scheme 29). 
 
 
Scheme 29. Synthesis of dihydroxylated cis cyclohexane-based β-amino esters 
 
The well-established protocol for the synthesis of dihydroxylated β-amino esters allowed 
the preparation of starting materials in enantiomerically pure form. Racemic β-lactam was 
subjected to enzyme-catalysed enantioselective ring opening, which was scaled up 
successfully118. Lactam (±)-86 was mixed with Lipolase, water was then added, and the mixture 
was shaken in an incubator shaker at 70 °C. Enantiomerically pure amino acid (-)-109 (e.e. > 
98%) and unreacted β-lactam (+)-86 (e.e. = 99%) were obtained and easily separated. Enantiomer 
(+)-86 was then transformed to optically pure β-amino carboxylate (+)-87 through ring opening 
with HCl/EtOH solution and N-Bz protection. Subsequent C-C double bond dihydroxylation with 
OsO4 resulted in vicinal diol (+)-88 (Scheme 30). 
 
Scheme 30. Enzymatic resolution of β-lactam (±)-86 and synthesis of diexo-β-amino esters 
 
The preparation of enantiomerically pure β-amino ester (-)-111 was attained through 
diastereomeric salt recrystallization. The reaction between racemic diendo-β-amino ester (±)-111 
and 1 equivalent of enantiomerically pure D-(-)-mandelic acid (-)-112 in EtOAc for 10 min 
yielded the corresponding diastereomeric salt mixture (±)-113. The salt mixture was then twice 
recrystallized from EtOAc-EtOH 10:1; the diastereomeric ratio was monitored by 1H NMR. The 
pure diastereomer was filtered off and treated with a saturated NaHCO3 solution, giving optically 
pure diendo-β-amino ester (-)-111 with e.e. = 99.9% (determined on a chiral HPLC Chiralpack IA 
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column, eluent: n-hexane–IPA (80:20), flow rate: 0.5 mL/min-1, detection at 210 nm). 
Benzoylation and stereoselective dihydroxylation resulted in enantiomer (-)-92 (Scheme 31). 
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Scheme 31. Synthesis of enantiomerically pure diendo-β-amino ester (-)-92 
 
Cyclopentane cis and trans β-amino esters were gained through the enzyme-catalyzed 
kinetic resolution of β-lactam by a slightly modified literature procedure118. The β-lactam (±)-94 
was mixed with CAL-B (Candida antarctica lipase B) in t-BuOMe and then shaken in an 
incubator shaker at 80 °C. The reaction was stopped by filtering off the enzyme at 50% 
conversion. The solvent was evaporated off and the unreacted β-lactam (-)-94 (e.e. = 99%) was 
crystallized out from diisopropyl ether. The filtered-off enzyme was washed with distilled water, 
and the water was evaporated off, yielding enantiomerically pure amino acid (+)-114 (e.e. > 
99%). Next, (-)-94 was treated with HCl/EtOH solution, and the following benzoylation and 
dihydroxylation led to optically pure diol (1R,2R)-(+)-96. The amino acid (+)-114 was 
transformed to trans β-amino carboxylate (1S,2S)-(+)-97 via esterification, group protection and 
base-induced epimerization procedures. The following dihydroxylation of (+)-97 led to formation 
of the enantiomer (1S,2R)-(+)-98 (Scheme 32). 
 
Scheme 32. Enzymatic resolution of β-lactam (±)-94 and synthesis of dihydroxylated cis and 
trans β-amino esters 
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Preliminary experiments were first conducted by utilizing the racemic substances, and the 
well-established strategy was then extended to the preparation of enantiomerically pure 
compounds. 
 
3.2. Functionalization of cispentacins through C-C oxidative cleavage of 
       diexo-and diendo-norbornene β-amino acids 
 
The syntheses of trans- and all-cis-disubstituted cispentacin derivatives were based on 
similar strategies, i.e. the transformation of the C-C double bond of carbocycles. The concept of 
the synthetic route, presented in Scheme 33, included functionalization of the ring C-C double 
bonds of diexo-norbornene β-lactam and diendo-β-amino acid through stereoselective 
dihydroxylation, and conversion of the vicinal diol by oxidative ring cleavage in order to generate 
the corresponding dialdehyde key intermediate, followed by Wittig transformation with different 
phosphoranylides and hydrogenation of the double bond formed. 
 
 
 
Scheme 33. Retrosynthetic scheme for the preparation of difunctionalized cispentacins from 
diexo- and diendo-norbornene derivatives 
 
The first step in the trans-disubstituted cispentacin derivatives synthesis involved the 
NaIO4-mediated oxidative ring cleavage40 of vicinal diol (±)-88 (preparation of which was 
described in the previous section). This resulted in dialdehyde key intermediate (±)-115, which 
proved to be a stable, isolable compound. The two formyl moieties of (±)-115 are in trans 
relationship relative to the carboxylate and amide groups, which is predetermined by the rigid 
structure of the starting dihydroxylated β-amino ester.  
The diformyl derivative (±)-115 was an excellent precursor for further transformations, e.g. 
the synthesis of dialkenylated cispentacins. In order to obtain these derivatives, dialdehyde (±)-
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115 was subjected to an in situ Wittig reaction119. First, methyltriphenylphosphonium bromide 
was treated with potassium tert-butoxide in dry THF for 15 min in order to generate the 
corresponding phosphoranylide, which was reacted with dialdehyde (±)-115 to furnish 
dialkenylated product (±)-116 in moderate yield. Similarly, the reaction of another phosphorane, 
generated from benzyltriphenylphosphonium bromide and potassium tert-butoxide, with diformyl 
derivative (±)-117, led to the corresponding dialkenylated Wittig product (±)-118. Subsequent 
catalytic hydrogenation of (±)-116 and (±)-118 resulted in dialkylated cispentacin derivatives (±)-
117 and (±)-119 in good yields (Scheme 34). 
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Scheme 34. Preparation of difunctionalized cispentacin derivatives (±)-117 and (±)-119 from 
dialdehyde (±)-115 
 
Further disubstituted cispentacins were obtained via analogous synthetic sequences by 
utilizing various commercially available phosphoranes. The Wittig reaction of dialdehyde (±)-115 
with methyl (triphenylphosphoranylidene)acetate in THF afforded compound (±)-120 in good 
yield. In a similar reaction with (triphenylphosphoranylidene)-2-propanone, olefinic product (±)-
122 was formed. Hydrogenolysis with a catalytic amount of Pd/C gave saturated final products 
(±)-121 and (±)-123 (Scheme 35). 
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Scheme 35. Preparation of difunctionalized cispentacin derivatives (±)-121 and (±)-123 from 
dialdehyde (±)-115 
 
The newly developed synthetic strategy allowed the preparation of novel cispentacin 
derivatives in enantiomerically pure form. The C-C bond cleavage of optically active 
dihydroxylated β-amino carboxylate (+)-88 with NaIO4 gave access to dialdehyde (+)-115. The in 
situ Wittig reaction allowed the preparation of dialkenylated compounds (+)-116 and (+)-118, and 
further the saturation of the olefinic bonds led to optically pure substituted cispentacins (-)-117 
and (+)-119 in good yields (Scheme 36). 
 
Scheme 36. Preparation of optically pure difunctionalized cispentacin derivatives (-)-117 and (+)-
119 
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The diformyl β-amino ester was further transformed into the corresponding enantiomers 
(+)-120 and (+)-122 in reactions with methyl (triphenylphosphoranylidene)acetate and 
(triphenylphosphoranylidene)-2-propanone, and catalytic reduction of the double bonds 
furnished saturated cispentacin derivatives (+)-121 and (+)-123 (Scheme 37). 
 
 
 
Scheme 37. Preparation of optically pure difunctionalized cispentacin derivatives (+)-121 
and (+)-123 
 
All the enantiomers were obtained with high optical purity (e.e. up to 97%). No 
epimerization was observed during the reactions, as proven by the absence of additional 
peaks in the 1H NMR spectra.  
The synthesis of all-cis-disubstituted cispentacin derivatives was based on a similar 
strategy as for the previously described trans-disubstituted analogues, i.e. the transformation 
of the C-C double bond of the carbocycle by dihydroxylation, oxidative ring cleavage and 
Wittig transformation of the dialdehyde formed. 
Preliminary experiments were performed with the racemic substances. The all-cis-
dialdehyde (±)-124 was obtained from diendo-dihydroxylated β-amino ester (±)-92 by 
oxidative ring cleavage with NaIO440. Next, the in situ Wittig reaction119 between diformyl 
derivative (±)-124 and the phosphorane generated from benzyltriphenylphosphonium bromide 
and t-BuOK in THF, furnished the all-cis distyryl cyclopentane derivative (±)-125. 
Surprisingly, the reaction of dialdehyde (±)-124 with the Wittig reagent generated from 
methyltriphenylphosphonium bromide yielded not the expected all-cis dialkenylated product 
after 1 h, but trans disubstituted compound (±)-116, which was earlier prepared from diformyl 
derivative (±)-115 (Scheme 38). In order to avoid the isomerization during the reaction with 
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methyltriphenylphosphonium bromide and t-BuOK, the experimental procedure was modified 
by inverse addition of the reagents: the in situ generated Wittig reagent was added to the 
dialdehyde to reduce the strong basic medium. However, after completion of the reaction, no 
traces of the all-cis product were detected: the reaction yielded exclusively the isomerized 
product (±)-116.  
 
Scheme 38. Preparation of disubstituted cispentacin derivatives (±)-126 and (±)-116 
 
The formation of isomerized product (±)-116 from dialdehyde (±)-124 can be explained 
by the isomerization of (±)-124, which was induced by t-BuOK, in a keto-enol equilibrium to 
the thermodynamically more stable (±)-115, followed by a Wittig reaction (Scheme 39). This 
led us to suppose that formation of the phosphorane from methyltriphenylphosphonium 
bromide required a longer time. Hence, the phosphonium salt was stirred with t-BuOK not for 
15 min, but for 2 h. When the resulting phosphorane was reacted with (±)-124 for either 30 
min or 1 h, product (±)-116 was again obtained.  
Hydrogenation of (±)-125 under catalytic conditions resulted in disubstituted derivative 
(±)-126 in good yield (Scheme 38). 
 
 
Scheme 39. Interconversion of (±)-115 and (±)-124 
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The dialdehyde (±)-124 was further subjected to the Wittig reaction with methyl 
(triphenylphosphoranylidene)acetate, giving dialkenylated cispentacin (±)-127 in 74% yield. 
The Ortep diagram of compound (±)-127 is presented in Figure 4. In the reaction with 
(triphenylphosphoranylidene)-2-propanone, (±)-124 gave the all-cis derivative (±)-129. 
Subsequent catalytic reduction of the olefinic bonds led to functionalized cispentacins (±)-128 
and (±)-130 (Scheme 40). 
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Scheme 40. Preparation of disubstituted cispentacin derivatives (±)-128 and (±)-130 
 
Figure 4. Ortep diagram of compound (±)-127 
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The synthetic protocol described above was further extended to the preparation of 
optically pure substances. Enantiomerically pure dihydroxylated β-amino ester (-)-92 was 
obtained according to the methodology presented earlier (Scheme 26). all-cis-Dialdehyde (-)-
124 was synthetized in optically pure form from (-)-92 by oxidative ring cleavage. The 
absolute configurations of the stereocenters in (-)-124 were determined by chemical 
correlation. When (-)-124 was treated with the Wittig reagent generated from 
methyltriphenylphosphonium bromide and t-BuOK, trans disubstituted derivative (+)-116 
was gained. Catalytic reduction of (+)-116 afforded (-)-117; the NMR data, HPLC ChiralPak 
IA, n-hexane/IPA, 0.5 ml/min, 210 nm, the same retention time: 10.05 min, opposite 
enantiomer 9.09) and comparison of the optical rotations revealed that this compound was 
identical to that prepared earlier from optically pure (+)-115: ethyl (1S,2R,3S,4R)-2-
benzoylamino-3,5-diformylcyclopentanecarboxylate, with known absolute configurations. 
Since the stereocentres were not affected during the transformations, it can be assumed from 
these results that (-)-124 is ethyl (1S,2R,3R,4S)-2-benzoylamino-3,5-
diformylcyclopentanecarboxylate, and hence (-)-92 has the 1R,2S,3R,4S absolute 
configuration.  
Optically active dialdehyde (-)-124 was transformed into dialkenylated Wittig product 
(+)-125 in the reaction with the benzyltriphenylphosphonium bromide-generated 
phosphorane. After C-C bond reduction, saturated compound (+)-126 was attained (Scheme 
41).  
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Scheme 41. Synthesis of optically pure disubstituted cispentacin derivatives (+)-126 and (-)-
117 
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The reaction of diformyl derivative (-)-124 with commercially available phosphoranes 
methyl (triphenylphosphoranylidene)acetate and triphenylphosphoranylidene-2-propanone 
gave access to optically pure (-)-127 and (+)-129, reduction of these products leading to (-)-
128 and (+)-130 in enantiomerically pure form (Scheme 42). 
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Scheme 42. Synthesis of enantiomerically pure disubstituted cispentacin derivatives (-)-128 
and (+)-130 
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3.3. Synthesis of disubstituted acyclic β2,3-amino acids from 2-amino-   
       3-cyclopentene carboxylic acid and 2-amino-3-cyclohexene  
       carboxylic acid 
 
The synthesis of β2,3-disubstituted open-chain amino acid derivatives was approached 
by the transformation of cis and trans cyclopentene β-amino acids and cyclohexene β-amino 
carboxylates through the above-described strategy, i.e. dihydroxylation, and oxidative ring 
opening, followed by the Wittig reaction. The stereochemistry of the acyclic products is 
predetermined by the configuration of the cyclic starting materials. The syntheses based on 
the cis and trans unsaturated 5-membered β-amino acid species from the racemic 1,3-
cyclopentadiene-derived β-lactam are expected to give acyclic anti and syn β2,3-amino acid 
derivatives, respectively, while syn or anti acyclic β-amino acids with a chain one carbon 
atom longer can be prepared by starting from 1,3- or 1,4-cyclohexadiene-derived β-lactams 
(Scheme 43). 
 
Scheme 43. Retrosynthetic route to β2,3-disubstituted acyclic amino esters 
 
Preliminary experiments were carried out with the racemic substances, and the 
protocol was further extended in order to obtain enantiomerically pure products. Open-chain 
dialdehyde intermediate (±)-131, prepared from diol (±)-96 via oxidative ring cleavage40, did 
not prove to be as stable as the previously presented diformyl cispentacin derivatives (±)-115 
  33 
and (±)-124. Hence further experiments were conducted by using the dialdehyde prepared in 
situ. The reactions of (±)-131 with phosphoranes generated from 
methyltriphenylphosphonium bromide or benzyltriphenylphosphonium bromide and t-BuOK 
furnished the corresponding diolefinated anti products (±)-132 and (±)-134 in moderate 
yields. Catalytic hydrogenation of these compounds led to saturated β-amino esters (±)-133 
and (±)-135 (Scheme 44). 
 
 
Scheme 44. Synthesis of disubstituted anti acyclic β-amino acid derivatives (±)-133 and  
(±)-135 
 
Further anti Wittig products (±)-136 and (±)-138 were synthetized from dialdehyde 
(±)-131 in reactions with commercially available phosphoranes, ethyl 
(triphenylphosphoranylidene)acetate or 1-(triphenylphosphoranylidene)-2-propanone. 
Subsequent olefinic bond saturation resulted in dialkylated β-amino esters (±)-137 and (±)-
139 in good yields (Scheme 45). 
 
Scheme 45. Preparation of disubstituted anti acyclic β-amino acid derivatives (±)-137 and 
(±)-139 
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The synthetic methodology was further successfully extended to the preparation of syn 
β-amino acid derivatives. Dialdehyde (±)-141, obtained from dihydroxylated β-amino 
carboxylate (±)-98 via NaIO4-mediated ring cleavage, exhibited similar instability to that of 
its earlier-described analogue (±)-131. The in situ Wittig reaction furnished the corresponding 
dialkenylated syn products (±)-141 and (±)-143, which were further transformed into the 
saturated β-amino esters (±)-142 and (±)-144 through a catalytic hydrogenation procedure 
(Scheme 46). 
 
 
 
Scheme 46. Synthesis of disubstituted syn acyclic β-amino acid derivatives (±)-142 and  
(±)-144 
 
The reaction of diformyl derivative (±)-140 with ethyl 
(triphenylphosphoranylidene)acetate or 1-(triphenylphosphoranylidene)-2-propanone gave the 
syn Wittig products (±)-145 and (±)-147. Subsequent Pd/C-catalysed hydrogenation led to 
compounds (±)-146 and (±)-148 in good yields (Scheme 47). 
 
Scheme 47. Preparation of disubstituted syn acyclic β-amino acid derivatives (±)-146 and  
(±)-148 
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The synthetic methodology was further extended for the preparation of all the open-
chain dialkylated products in enantiomerically pure form. Optically pure dialkenylated 
products (+)-132 and (-)-134 were prepared from dialdehyde 131 via the Wittig reaction. The 
saturation of these products furnished anti β-amino carboxylates (-)-133 and (-)-135 (Scheme 
48). 
 
 
 
Scheme 48. Synthesis of optically pure disubstituted anti acyclic β-amino acid derivatives (-)-
133 and (-)-135 
 
Further optically active anti β-amino acid derivatives (+)-136 and (-)-138 were 
synthetized by treating diformyl compound 131 with commercially available phosphoranes. 
Subsequent catalytic hydrogenation led to enantiomers (-)-137 and (-)-139 (Scheme 49). 
 
 
Scheme 49. Preparation of disubstituted enantiomerically pure anti acyclic β-amino acid 
derivatives (-)-137 and (-)-139 
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Next, enantiomerically pure dialdehyde 140 was transformed into acyclic syn Wittig 
products (-)-141 and (-)-143. Reduction of the olefinic bond afforded final products (-)-142 
and (-)-144 in 99% enantiomeric purity (Scheme 50). 
 
Scheme 50. Synthesis of disubstituted optically active syn acyclic β-amino acid derivatives  
(-)-142 and (-)-144 
 
Finally, similar synthetic procedures afforded the dialkenylated β-amino acid 
derivatives (-)-145 and (-)-147 in enantiomerically pure form. Catalytic hydrogenation of 
these products in the presence of Pd/C gave access to syn saturated final products (-)-146 and 
(-)-148 (Scheme 51).  
 
Scheme 51. Preparation of disubstituted syn acyclic β-amino acid derivatives (-)-146 and (-)-
148 in optically pure form 
 
Following the extension of our study with novel Wittig reagents on the synthesis of 
open-chain β-amino acid derivatives, the synthetic approach towards dialkylated β2,3-amino 
acid species based on cyclohexene β-amino carboxylates was demonstrated.  
Diformyl derivative (±)-149 was synthetized from dihydroxylated β-amino ester (±)-
102 through an oxidative ring cleavage protocol, which was previously successfully applied 
for the preparation of cispentacin-based diformyl derivatives (±)-115 and (±)-124 or open-
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chain dialdehydes (±)-131 and (±)-140. It should be noted that dialdehyde (±)-149 displayed 
similar instability to that of the previously described acyclic dialdehydes (±)-131 and (±)-140. 
As it could not be isolated, further experiments were conducted with dialdehyde generated in 
situ. The Wittig reaction between (±)-149 and methyl (triphenylphosphoranylidene)acetate or 
(triphenylphosphoranylidene) acetonitrile resulted in anti open-chain dialkenylated products 
(±)-150 and (±)-151. The following hydrogenation under catalytic conditions furnished 
saturated β-amino esters (±)-152 and (±)-153 in good yields. Further anti disubstituted 
compounds (±)-154 and (±)-155 were obtained via the reactions of dialdehyde (±)-149 and in 
situ generated ylides from methyltriphenylphosphonium bromide or 
benzyltriphenylphosphonium bromide. Subsequent double bond reduction yielded β-amino 
acid derivatives (±)-156 and (±)-157 (Scheme 52).  
 
 
Scheme 52. Preparation of disubstituted anti open-chain derivatives (±)-152, (±)-153, (±)-156 
and (±)-157 
 
The above synthetic protocol was subsequently extended to the preparation of open-
chain syn β-amino esters. The diformyl derivative (±)-158 synthetized from diol (±)-104 
demonstrated similar instability to that of the previously described acyclic analogues. 
Difunctionalized Wittig products (±)-159, (±)-160 and (±)-161 were formed by treating 
dialdehyde (±)-158 with commercially available phosphoranes. Subsequent catalytic 
hydrogenation resulted in saturated acyclic compounds (±)-162, (±)-163 and (±)-164 in good 
yields. The reaction of dialdehyde (±)-158 with the ylide generated from 
benzyltriphenylphosphonium bromide then afforded the disubstituted Wittig product (±)-165, 
which was further reduced to derivative (±)-166 (Scheme 53). For unknown reasons, in the 
reaction of dialdehyde (±)-158 with the ylide generated from methyltriphenylphosphonium 
bromide, no product formation was observed.  
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Scheme 53. Synthesis of disubstituted syn open-chain derivatives (±)-162, (±)-163, (±)-164 
and (±)-166 
 
Dialdehyde (±)-167 was obtained from the dihydroxylated β-amino carboxylate (±)-108 
via oxidative ring cleavage. The dialkenylated species (±)-168, (±)-169, (±)-170 and (±)-174, 
isomers of earlier prepared derivatives (Schemes 52 and 53), were gained via the Wittig 
reaction. Subsequent olefinic bond reduction furnished novel anti β-amino acid derivatives 
(±)-171, (±)-172, (±)-173 and (±)-174 (Scheme 54). As in the previous case, the in situ Wittig 
reaction between dialdehyde (±)-167 and the ylide generated from 
methyltriphenylphosphonium bromide failed.  
 
 
Scheme 54. Preparation of disubstituted anti open-chain derivatives (±)-171, (±)-172, (±)-173 
and (±)-175 
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4. SUMMARY 
 
A novel stereocontrolled synthetic access route has been developed to difunctionalized 
cispentacin derivatives from diexo- and diendo-norbornene β-amino acids and acyclic β2,3-
amino acid species derived from cis- or trans- β-aminocyclopentene and 
cyclohexenecarboxylates. The syntheses were based on transformation of the C-C double 
bond in the cyclic starting materials by stereoselective dihydroxylation with OsO4, followed 
by NaIO4-mediated oxidative ring cleavage of the corresponding diols, with subsequent 
Wittig transformations of the dialdehyde intermediates and Pd/C-catalysed hydrogenations of 
the dialkenylated β-amino esters formed.  
Preliminary experiments were performed with the racemic substances, and the protocol 
was then extended to enantiomerically pure substances. Racemic β-amino esters 87, 91, 95, 
97, 101, 103 and 107 were synthetized as required starting materials by β-lactams ring 
opening, followed by N-protection. Bicyclic diendo-β-amino ester 91 was obtained from 
bicyclic diendo-anhydride via ring opening, followed by Hoffmann degradation, esterification 
and N-Bz protection. Stereoselective dihydroxylation of these compounds by means of NMO 
and a catalytic amount of OsO4 furnished dihydroxylated β-amino esters 88, 92, 96, 98, 102, 
104 and 108 (Schemes 25, 26, 27, 28 and 29).  
The well-established protocol for the synthesis of dihydroxylated β-amino esters allowed 
the preparation of starting materials in enantiomerically pure form. Racemic β-lactam 86 was 
subjected to enzyme-catalyzed enantioselective ring opening, resulting in enantiomerically pure 
amino acid (-)-109  and unreacted β-lactam (+)-86. Enantiomer (+)-86 was then transformed to 
optically pure diol (+)-88 through ring opening, N-Bz protection and dihydroxylation (Scheme 
30). 
The preparation of enantiomerically pure β-amino ester (-)-92 was attained through 
diastereomeric salt recrystallization. The reaction between racemic diendo-β-amino ester (±)-111 
and enantiomerically pure D-(-)-mandelic acid (-)-113 yielded the corresponding diastereomeric 
salt mixture (±)-113. This mixture was then recrystallized, and the diastereomeric ratio was 
monitored by 1H NMR. The pure diastereomer was treated with saturated NaHCO3 solution to 
give optically pure diendo-β-amino ester (-)-111 with ee = 99.9%. Subsequent benzoylation and 
stereoselective dihydroxylation resulted in enantiomer (-)-92 (Scheme 31). 
Cyclopentane cis and trans β-amino esters were gained through the enzyme-catalysed 
kinetic resolution of β-lactam. Enantiomerically pure amino acid (+)-114 and unreacted β-lactam 
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(-)-94 were obtained and separated. Next, (-)-94 was treated with HCl/EtOH solution, and the 
following benzoylation and dihydroxylation led to optically pure diol (1R,2R)-(+)-96. Amino acid 
(+)-114 was transformed to dihydroxylated trans β-amino carboxylate (1S,2R)-(+)-98 via 
esterification, group protection, base-induced epimerization and dihydroxylation procedures 
(Scheme 32). 
The C-C bond cleavage of optically active dihydroxylated β-amino carboxylate (+)-88 with 
NaIO4 gave access to ethyl 2-benzamido-3,5-diformylcyclopentanecarboxylate (+)-115. The in 
situ Wittig reaction allowed the preparation of dialkenylated compounds (+)-116 and (+)-118, and 
the saturation of the olefinic bonds led to the optically pure substituted cispentacins ethyl 2-
benzamido-3,5-diethylcyclopentanecarboxylate (-)-117 and ethyl 2-benzamido-3,5-
diphenethylcyclopentanecarboxylate (+)-119 (Scheme 34). 
The diformyl β-amino ester was further transformed into the corresponding enantiomers 
(+)-120 and (+)-122 by reaction with methyl (triphenylphosphoranylidene)acetate and 
(triphenylphosphoranylidene)-2-propanone, and catalytic reduction of the double bonds 
furnished saturated cispentacin derivatives 3,3'-dimethyl 4-benzamido-5-
(ethoxycarbonyl)cyclopentane-1,3-diyl)dipropanoate (+)-121 and ethyl 2-benzamido-3,5-
bis(3-oxobutyl)cyclopentanecarboxylate (+)-123 (Scheme 35). 
The syntheses of all-cis-disubstituted cispentacin derivatives were based on a similar 
strategy. all-cis-Ethyl 2-benzoylamino-3,5-diformylcyclopentanecarboxylate (-)-124 was 
synthetized in optically pure form from (-)-92 by oxidative ring cleavage. Dialdehyde (-)-124 
was transformed into dialkenylated Wittig product (+)-125 through reaction with the 
benzyltriphenylphosphonium bromide-generated phosphorane. After C-C bond reduction, 
saturated ethyl 2-benzoylamino-3,5-diphenethylcyclopentanecarboxylate (+)-126 was attained 
(Scheme 38).  
The reaction of ethyl 2-benzoylamino-3,5-diformylcyclopentanecarboxylate (-)-124 
with commercially available phosphoranes gave access to optically pure (-)-127 and (+)-129, 
reduction of  these products leading to ethyl (1S,2R,3R,4S)-2-benzoylamino-3,5-bis-(2-
methoxycarbonylethyl)cyclopentanecarboxylate (-)-128 and ethyl 2-benzoylamino-3,5-bis-(3-
oxobutyl)cyclopentanecarboxylate (+)-130 (Scheme 40). 
The synthesis of β2,3-disubstituted open-chain amino acid derivatives was approached 
by the transformation of cis and trans cyclopentene and cyclohexene β-amino acids through 
the above-described strategy. Optically pure dialkenylated products (+)-132 and (-)-134 were 
prepared from dialdehyde 131 via the Wittig reaction. The saturation of these products 
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furnished anti β-amino carboxylates ethyl 3-benzamido-2-propylpentanoate (-)-133 and ethyl 
3-benzamido-5-phenyl-2-(3-phenylpropyl)pentanoate (-)-135 (Scheme 44). 
Further optically active anti β-amino acid derivatives triethyl 3-benzamidoheptane-
1,4,7-tricarboxylate (+)-137 and ethyl 3-benzamido-6-oxo-2-(4-oxopentyl)heptanoate (-)-139 
were synthetized by treating diformyl compound 131 with commercially available 
phosphoranes and subsequent catalytic hydrogenation (Scheme 45). 
Next, enantiomerically pure dialdehyde 140 was transformed into the acyclic syn Wittig 
products ethyl 3-benzamido-2-propylpentanoate (-)-142 and ethyl 3-benzamido-5-phenyl-2-
(3-phenylpropyl)pentanoate (-)-144. (Scheme 46). 
Finally, similar synthetic procedures afforded the dialkenylated β-amino acid 
derivatives (-)-146 and (-)-148 in enantiomerically pure form (Scheme 47).  
Following the extension of our study with novel Wittig reagents to the synthesis of 
open-chain β-amino acid derivatives, a synthetic approach towards dialkylated β2,3-amino 
acid species based on cyclohexene β-amino carboxylates was developed. Diformyl derivative 
149 was synthetized from dihydroxylated β-amino ester 102 through an oxidative ring 
cleavage protocol. The Wittig reaction between 149 and methyl 
(triphenylphosphoranylidene)acetate or (triphenylphosphoranylidene)acetonitrile resulted in 
anti open-chain dialkenylated products 150 and 151. The following hydrogenation under 
catalytic conditions furnished saturated β-amino esters 4-ethyl 1,8-dimethyl 5-
benzamidooctane-1,4,8-tricarboxylate 152 and ethyl 3-benzamido-6-cyano-2-(3-
cyanopropyl)hexanoate 153. Further anti disubstituted compounds ethyl 3-benzamido-2-
propylhexanoate 156 and ethyl 3-benzamido-6-phenyl-2-(3-phenylpropyl)hexanoate 157 were 
obtained via in situ Wittig reactions and subsequent double bond reduction (Scheme 52).  
The above synthetic protocol was subsequently extended to the preparation of open-
chain syn β-amino esters. Difunctionalized Wittig products 159, 160 and 161 were formed by 
treating dialdehyde 158 with commercially available phosphoranes. The following catalytic 
hydrogenation resulted in saturated acyclic compounds 4-ethyl 1,8-dimethyl-5-
benzamidooctane-1,4,8-tricarboxylate 162, ethyl 3-benzamido-6-cyano-2-(3-
cyanopropyl)hexanoate 163 and ethyl 3-benzamido-7-oxo-2-(4-oxopentyl)octanoate 164. The 
reaction of dialdehyde 158 with the ylide generated from benzyltriphenylphosphonium 
bromide then afforded the disubstituted Wittig product 165, which was further reduced to 
derivative 166 (Scheme 53).  
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Dialdehyde 167 was obtained from the dihydroxylated β-amino carboxylate 108 via 
oxidative ring cleavage. The dialkenylated species 4-ethyl 1,8-dimethyl 3-benzamidooctane-
1,4,8-tricarboxylate 171, 2-ethyl 1-benzamido-3-cyanopropyl)-6-cyanohexanoate 172, 2-ethyl 
1-benzamido-4-oxopentyl)-7-oxooctanoate 173 and 2-ethyl-1-benzamido-3-phenylpropyl)-6-
phenylhexanoate 175 were gained via Wittig reactions and subsequent olefinic bond reduction 
(Scheme 54).  
It should be emphasized that the stereochemistry of the target difunctionalized β-
amino esters was predetermined by the configurations of the cyclic starting materials. Since 
the stereogenic centres of the starting materials were not affected during the transformations, 
their stereochemistry determined the configurations of the asymmetric centres in the final 
products.  
The presented synthetic methodology proved to be simple, efficient and completely 
stereocontrolled. Through use of this synthetic approach, 54 novel cyclic and open-chain β-
amino acid derivatives have been obtained. It may be generalized and applied for the 
synthesis of a variety of substituted cyclic and open-chain β-amino acid derivatives. 
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